Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Myelodysplastic Syndromes 4Leukemia, Myelomonocytic, Chronic 3Leukemia, Myeloid, Acute 2Thrombocythemia, Essential 1Recurrence 1Primary Myelofibrosis 1Preleukemia 1Polycythemia Vera 1Myeloproliferative Disorders 1Leukemia, Myeloid 1Leukemia 1Hematologic Diseases 1Bone Marrow Diseases 1

Interventions

fludarabine 3Melphalan 3fludarabine phosphate 2Whole-Body Irradiation 2Tacrolimus 2Peripheral Blood Stem Cell Transplantation 2Patient Reported Outcome Measures 2Mycophenolic Acid 2Mesna 2Cyclophosphamide 2Busulfan 2Bone Marrow Transplantation 2venetoclax 1spartalizumab 1sabatolimab 1ruxolitinib 1lintuzumab 1Sertraline 1Sampling Studies 1Lenalidomide 1Decitabine 1CPI-0610 1Biopsy 1Azacitidine 1Alemtuzumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Preleukemia × sabatolimab × Myeloid × Clear all
NCT03066648 2025-05-18

Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With AML or High Risk MDS

Novartis

Phase 1 Completed
241 enrolled
MyeloidOther hematologic neoplasm

Bone Marrow Diseases, Hematologic Diseases, Leukemia, Leukemia, Myeloid, Myelodysplastic Syndromes, Preleukemia, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡